Cutaneous adverse events associated with vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma: an observational study of 30 treated patients and presentation of a management algorithm

被引：0
|
作者：
Sinha, R. [1 ]
Edmonds, K. [2 ]
Newton-Bishop, J. A. [3 ]
Gore, M. [2 ]
Larkin, J. [2 ]
Fearfield, L. A. [1 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Univ Leeds, Leeds, W Yorkshire, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2012年 / 167卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [1] Vemurafenib in Patients With BRAF V600E Mutation-Positive Advanced Melanoma
    Ravnan, Marcus C.
    Matalka, Mazen S.
    CLINICAL THERAPEUTICS, 2012, 34 (07) : 1474 - 1486
  • [2] Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations
    Sinha, R.
    Larkin, J.
    Gore, M.
    Fearfield, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (04) : 1024 - 1031
  • [3] Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
    Andrea P Sponghini
    David Rondonotti
    Marco Giavarra
    Roberto Giorgione
    Francesca Platini
    Journal of Translational Medicine, 13 (Suppl 1)
  • [4] BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
    Ribas, A.
    Kim, K. B.
    Schuchter, L. M.
    Gonzalez, R.
    Pavlick, A. C.
    Weber, J. S.
    McArthur, G. A.
    Hutson, T. E.
    Flaherty, K. T.
    Moschos, S. J.
    Lawrence, D. P.
    Hersey, P.
    Kefford, R. F.
    Chmielowski, B.
    Puzanov, I.
    Li, J.
    Nolop, K. B.
    Lee, R. J.
    Joe, A. K.
    Sosman, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma
    Grippo, J. F.
    Zhang, W.
    Heinzmann, D.
    Yang, K. H.
    Wong, J.
    Joe, A. K.
    Munster, P.
    Sarapa, N.
    Daud, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 103 - 111
  • [6] BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients
    Tas, Faruk
    Erturk, Kayhan
    DERMATOLOGIC THERAPY, 2020, 33 (02)
  • [7] Evaluating the Safety and Tolerability of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Metastatic BRAF V600E/K Mutation-positive Cutaneous Melanoma
    Wang, T. W.
    Smith, J. L.
    Carlino, M.
    Burmeister, B.
    Pinkham, M. B.
    Fogarty, G. B.
    Christie, D.
    Estall, V.
    Shackleton, M.
    Wolfe, R.
    Phuong, T. L. T.
    Paton, E. J.
    Steel, V.
    Williams, N. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S133 - S134
  • [8] Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients
    Tas, F.
    Erturk, K.
    NEOPLASMA, 2019, 66 (04) : 631 - 636
  • [9] Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
    Nowara, Elzbieta
    Huszno, Joanna
    Slomian, Grzegorz
    Nieckula, Jaroslaw
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2016, 33 (01): : 52 - 56
  • [10] Determination of the BRAF V600E mutation in Uruguayan melanoma patients
    Eugenia Mazzei, Maria
    Hochman, Jimena
    Manrique, Gonzalo
    Luisa Marino, Ana
    Beatriz Delgado, Lucia
    Angel Martinez, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345